An investigation on behalf of investors in BioScrip Inc (NASDAQ:BIOS) shares over potential wrongdoing at BioScrip Inc (NASDAQ:BIOS) was announced.
San Diego, CA -- (SBWIRE) -- 03/19/2018 -- An investigation was announced investors in shares of BioScrip Inc (NASDAQ:BIOS) was announced over potential breaches of fiduciary duties by certain officers and directors at BioScrip Inc.
Investors in shares of BioScrip Inc (NASDAQ:BIOS) should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain BioScrip Inc officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
Denver, CO based BioScrip, Inc. is engaged in providing infusion solutions. BioScrip Inc reported that its annual Total Revenue declined from $982.22 million in 2015 to $935.59 million in 2016 and that its Net loss declined from $299.71 million in 2015 to $41.51 million in 2016.
On March 8, 2018, BioScrip released its preliminary fourth quarter and full year financial results, but also disclosed that the Company had begun an internal accounting review because it "identified internal control deficiencies in connection with account reconciliations for certain asset and liability accounts," and that this may cause a delay in the filing of its Form 10-K. The Company additionally announced that it "has identified and will report a material weakness related to certain spreadsheets used to calculate periodic adjustments to" certain accounts.
Those who purchased shares of BioScrip Inc (NASDAQ:BIOS), have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego